RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights

NEXT STORY
Prospective Data Demonstrates Effective Pain Relief and Improved Function Using Medtronic’s Evolve(SM) Workflow with Spinal Cord Stimulation
PREV STORY
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies

AUSTIN, Texas, Aug. 29, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology ...

author_avatar
NASDAQ Market News

LGC Capital Announces Agreement to Acquire a Significant Interest in Fully Licenced European Pharmaceutical Company, Freia Farmaceutici Srl.

author_avatar
NASDAQ Market News

ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting

– Controlled IL-12 gene therapy turns cold tumors hot –– MRI indicates decreasing size ...

author_avatar
NASDAQ Market News